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Fig. 2. Intraluminal vascular control using #5 Fogarty catheter passed retrograde from distal 
axillary artery. 
concept; however, the long-term durability of these intra- 
vascular prosthesis needs to be determined. 
In this case, a PTFE graft was used because vein graft 
was not available. It worked well, but long-term follow-up 
was not possible because the patient died 8 months later. 
Both vein and PTFE grafts have been used successfully in 
the axillary position. 
Paul M. Orecchia, MD 
David Calcagno, MD 
Richard A. Razzino, MD 
Department ofSurgery 
Division of Vascular Surgery 
Pinnacle Health at Polyclinic Hospital 
Harrisburg, Pa. 
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Regarding "Report ing  standards in venous disease: 
An update" 
To the Editors: 
We read with interest he recent article "Reporting 
standards in venous disease: An update" by Porter et al. 
(~ Vasc Surg 1995;21:635-45). In this articlc, which is one 
of the dominant papers on this subject, the authors report 
the risk factors and predisposing conditions in deep venous 
thrombosis (DVT) of the lower extremity and document 
risk scores. 
We are sorry to state that Behqet's yndrome was not 
mentioned as one of the predisposing conditions in this 
report. Behqet's disease is not a rare disease, especially in the 
Middle East and Japan. It is known that Behget's disease is 
a vasculitis with multiple organ involvement; its cause, 
however, is unl~aown. It is characterized with classic triad of 
oral mucosa, skin, and eye involvement. Vascular involve- 
ment rate is between 7% and 29% in the literature. 1 Kuzu et 
al. reported 1200 cases of Behqet's disease with 14.4% 
venous and 1.6% arterial involvement. Lower extremity 
DVT is also reported as 12.8% in the same series. 
Among the 63 DVT patients in our clinic, Behqet's 
disease complication was diagnosed in three young men. 
Behqet's disease is one of the causes of hypercoagula- 
bility. 2, Disease can be onset with vascular complications 
instead of classic triad.3 Venous complications are dominant 
in the vascular involvement. Vena cava inferior, vena cava 
superior, upper extremity, and cerebral sinus thrombosis are 
seen as well as lower extremity thrombosis. 1 
We believe that Behget's disease must be considered as 
one of the etiologic factors and predisposing conditions in 
the Report of the Venous Disease Consensus Committee. 
Hasan Sunar, MD 
Yener Ydriik, MD 
Department ofThoracic and Cardiovascular Surgery 
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Reply 
To the Editors: 
I thank Drs. Sunar and YSrfik for calling to our attention 
the above-detailed information on Behqet's disease. This 
points out the classic dilemma faced by the authors of a 
consensus document attempting to strike balance between 
sufficient detail to be useful and becoming bogged down in 
minutiae. 
Behqet's disease is clearly endemic in Turkey, and 
remarkable series have been published indicating that 
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about one fourth of the afflicted patients may suffer from 
venous thrombosis. Thankfully, Behqet's disease is van- 
ishingly rare in many parts of the world, including the 
United States. Thus I made the decision to not list 
Behqet's disease in the paper. I do note that we include 
a section entitled "Prethrombotic States," where I do 
believe Behqet's disease could be adequately placed in 
using ouJr reporting standards. 
In summary, despite the remarkable prevalence of 
Behqet's disease in Turkey, its minimal prevalence inmost of 
the rest of the world, in my opinion, justifies our omission 
of this specific condition. 
John M. Porter, MD 
Division of Vascular Surgery 
Oregon Health Sciences University 
3181 S.W. Sam Iackson Park Rd., OPll 
Portland, OR 97201-3098 
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L IFEL INE  FOUNDATION RESEARCH AWARD 
The Lifeline Foundation of the Society for Vascular Surgery and the International Society for 
Cardiovascular Surgery, North American Chapter, invites grant applications for funding of meritori- 
ous research by young surgical investigators. The awards are intended for surgeons who have com- 
pleted their formal surgical education in general surgery and who have completed or are in an 
advanced training program in vascular surgery. 
To be considered for selection a candidate: 
1. Should be certified by the American Board of Surgery or have completed the rcqnirements for
certification 
2. Should submit an application within 5 years of completion of an approved vas- 
cular surgery residency training program 
3. Must have either a faculty appointment i  an approved medical school in the United States or 
Canada or have received an academic appointment within the guidelines of the applicant's 
institution 
Grant awards are not intended to supplement salary, which will remain the responsibility ofthe 
institution i which the awardee holds an appointment. The awardee isexpected to devote asignifi- 
cant amount of time to the funded project. A progress report must be presented to the Executive 
Committee of the Foundation by the following April 1, and, on completion ofthe project, abrief oral 
report is to be presented tothe memberships of the two societies during a plenary session at the Joint 
Annual Meeting. 
A grant awards committee will review competitive applications. It is anticipated that two grants 
will be awarded annually totaling $50,000 each to include indirect costs. The $ 50,000 grant includes 
funding to enable the awardee to attend the Joint Annual Meeting of the Vascular Societies to receive 
his or her award in the year of selection. Each award will be for 1 year with the option to extend for an 
additional year. 
Holders of substantial research awards, such as an NIH ROI, FIRST Award, or similar support, 
are ineligible. The applicant must append to the application the abstracts of any funded or pending 
grants. 
Grant applications may be obtained from: 
Chairman 
The Lifeline Foundation 
Thirteen Elm St. 
Research and Education Committee 
Manchester, MA 01944 
(508)526-8330 
The deadline for receiving applications inthe Foundation office is January 15,1997. Funds 
will be awarded by July 1, 1997. 
